Immunocore

7 results

Malin was the subject of a board and management overhaul in the middle of last year that led to a refocusing of its disparate portfolio of investments around four priority assets

Irish life sciences investment company Malin Corp, whose shares have plunged in recent months amid fears over the future of embattled Woodford Investm(...)

Ian Curley and other executives are  due to present details of the group’s review at a capital markets day in London early next month

Dublin-listed life sciences investment firm Malin has announced the departure of chief executive Adrian Howd after just one year in the post. The tro(...)

Malin had raised €407 million in equity capital as of the end of June 2017

Listed life sciences company Malin, whose backers include the Irish State, is to raise as much as €31 million through a placing of new shares. The Du(...)

Malin has invested more than €313 million across 16 life sciences companies since it was established early last year.

Malin, the Irish-based life sciences company set up by a number of former Elan executives last year, reported a €36.1 million pretax loss for the six(...)

Malin chief executive Kelly Martin, who was previously boss at Elan

Malin, the Irish-based life sciences company set up by a number of former Elan executives last year to invest in privately held life science assets, h(...)

Malin has  invested in 14 businesses

Listed life sciences investment group Malin has reported its maiden set of results. Excluding the costs of establishing the company, Malin reported a (...)

Immunocore, which was spun out of Oxford University in 2008, is developing novel T cell receptor (TCR) based therapies with the potential to treat a variety of cancers, viral infections and autoimmune diseases

Malin, the Irish-based company set up by a number of former Elan executives to invest in privately held life science assets, has invested $80 million (...)